A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Inclusion Criteria:Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET) Myelofibrosis (MF), or post- Polycythemia vera (PV) MFTreated with FEDR and initiated treatment after 16 August 2019.Received prior treatment with RUX.Had spleen assessed at time of initiation of FEDR by palpation.Able to read and speak EnglishWilling to provide informed consentWilling to provide permission to the site to release her/his medical information to the study investigators according to the study-specific eCRFWilling to complete the baseline survey prior to first FEDRExclusion Criteria:Past or current participant in any FEDR-related clinical trial